SEATTLE--(BUSINESS WIRE)--Today, Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technological and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients.
This merger announcement follows their successful partnership in January 2022 which enables streamlined access to the next generation of safe, universal, cost-effective, off-the-shelf" iPSCs. Pluristyx/panCELLas iPSCs are generated through a proprietary mRNA-based technology and are conveniently available in a try-before-you-buy research evaluation model requiring low up-front licensing fees. Packaged in Pluristyxs Ready-to-Differentiate format, iPSCs containing panCELLas FailSafe and hypoimmunogenic technologies offer customers, at any stage of product development, the ability to rapidly assess and select lines for further development and manufacturing. Since Plurisytx/panCELLa iPSCs are sourced from clinical-grade material, commercial partners can readily transition from development to therapeutic manufacturing.
Regarding this merger, Mahendra Rao, Co-Chairman of the Board at panCELLa and CEO of Implant Therapeutics, commented, We are extremely excited to be joining forces with Pluristyx. From the start of our collaboration, it was clear that the expertise and strong track record in cell therapy development within the Pluristyx team was the perfect fit to maximize the customer benefit from our technologies. By coming together, we can offer clients an industry-leading suite of technologies and services for the next generation of cell therapies.
Benjamin Fryer, Chief Executive Officer, Pluristyx said: In discussions with customers, it became evident that panCELLas hypoimmune and FailSafe technologies are seen as industry gold-standards. This merger takes us one step farther in our journey to become the leading provider of iPSC and cell therapy solutions for research, diagnostic, and clinical applications. Together with the expertise and technology portfolio of panCELLa, we can now provide a full suite of tools and provide the fastest path to gene-edited iPSC-based therapies.
The merged companies will retain the Pluristyx name with panCELLa becoming a wholly owned subsidiary of Pluristyx. Benjamin Fryer will continue as the Chief Executive Officer and Mahendra Rao will take on the role of Chief Science Officer. Current Pluristyx and panCELLa executives will be Jason Carstens as the Chief Operating Officer, Brian Hawkins as the Chief Technology Officer, Kaye Reiter as General Counsel, Jake Krembil as VP of Business Development/Toronto Site Lead, and James Laing as VP of Finance.
About Pluristyx
Pluristyx is a privately held biotechnology company based in Seattle, WA that offers consulting, wet-lab and GMP banking services, and pluripotent stem cell products to support novel therapeutic developers. Pluristyx helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The Pluristyx team has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. To learn more, visit http://www.pluristyx.com or email info@pluristyx.com.
About panCELLa
Co-founded in 2015 by Dr. Andras Nagy, PhD, stem cell biologist and Dr. Armand Keating, MD, PhD, clinical scientist, and hematologist, panCELLa is a privately held early-stage biotechnology firm based on the innovative technology developed in Dr. Andras Nagys lab at the Sinai Health System (SHS) in Toronto, Canada. panCELLa has created platforms that allow for the development of safe, universal, cost-effective, off-the-shelf therapeutic cell products for medicine. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive FailSafe and Cloaked Cells/iACT cells. panCELLa continues its internal R&D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination and tolerization. To learn more, visit https://pancella.com.
About Implant Therapeutics
A subsidiary of panCELLa, Implant is a biotechnology company based in Maryland, United States. As a developer of genetically engineered stem cells, Implant combines the advantages of iPSC-MSC with panCELLas exclusive safety platforms to deliver the ultimate therapeutic MSC products. To learn more, visit: http://www.implant-rx.com
See the original post:
Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement - Business Wire
- Johns Hopkins Scientists Have Developed a Nanobody That May Treat Parkinson's Disease - SciTechDaily - September 25th, 2022
- UMD students contribute to tech, health fields with summer research projects - The Diamondback - September 16th, 2022
- Pair of Hopkins teams receive $200K in technology grants - Maryland Daily Record - August 22nd, 2022
- RoosterBio and AGC Biologics team up to accelerate manufacture of cell and exosome therapies - BioPharma-Reporter.com - August 22nd, 2022
- Stem Cell Transplant Reverses Sickle Cell Disease in Adults - July 3rd, 2022
- LONGEVERON INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - May 15th, 2022
- Top Ways To Rejuvenate Your Body And Improve Your Well-being - The Southern Maryland Chronicle - April 19th, 2022
- BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress... - April 19th, 2022
- Synthetic biology's past, present and future explored in timely new account - Winnipeg Free Press - April 6th, 2022
- US is Out of Step on Primate Research With Rest of World - NewsClick - October 5th, 2021
- A Look Inside A Termite's Gut Wins The 11th Annual Nikon Small World in Motion Competition - PRNewswire - August 18th, 2021
- What really happened in Wuhan? - The Sunday Guardian Live - The Sunday Guardian - June 6th, 2021
- UMD Researchers Perform Crucial Proof-of-Concept ... - December 20th, 2020
- US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY - December 20th, 2020
- Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer | DNA RNA and Cells | News Channels -... - December 7th, 2020
- Trump was one of the first 10 patients to get an experimental COVID-19 treatment under special use - Yahoo News - October 8th, 2020
- New toilet, a VR camera and science experiments are heading to t - KAKE - October 8th, 2020
- ShoreRivers awarded DNR grant for two restoration projects - MyEasternShoreMD - August 26th, 2020
- CRISPR cows could boost sustainable meat production, but regulations and wary consumers stand in the way - Genetic Literacy Project - August 26th, 2020
- Over $8M in 2020 Stem Cell Funding Awards Continue to Fuel Marylands Leading Cell Therapy Industry - BioBuzz - June 24th, 2020
- Researchers develop nanoengineered bioink to 3D print functional bone tissue - 3D Printing Industry - May 27th, 2020
- 'Virus Goes In, Virus Goes Out': Advocates Call For Release Of More Low-Level Prisoners To Stem Infection Rate - Kaiser Health News - May 22nd, 2020
- What Do New Neurons in the Brains of Adults Actually Do? - The Scientist - May 7th, 2020
- David C. Karli is Offering a New Ray of Hope Through Regenerative Medicine - RESPECT. - May 3rd, 2020
- Could Innate Immunology Save Us From the Coronavirus? - The New York Times - May 3rd, 2020
- Watch: Hogan orders closure of bars, restaurants, theaters and gyms, restricts gatherings - Maryland Daily Record - March 22nd, 2020
- Dr Borehams Crucible: The small cap biotechs trying to make a buck from coronavirus - Stockhead - March 9th, 2020
- The Aussie Biotech Companies Trying To Make A Buck From Coronavirus - D'Marge - March 9th, 2020
- Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery - Science Magazine - March 4th, 2020
- Maryland Stem Cell Center Consortium & Core Facility ... - March 4th, 2020
- Serving those who serve - The Hub at Johns Hopkins - November 14th, 2019
- BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic... - November 6th, 2019
- VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web - November 6th, 2019
- Contrasting of Applied Therapeutics Inc. (APLT) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly - November 6th, 2019
- Reviewing Synthetic Biologics Inc. (SYN)'s and Asterias Biotherapeutics Inc. (:)'s results - FinanceMercury - November 6th, 2019
- Comparing of Neuralstem Inc. (CUR) and Allakos Inc. (NASDAQ:ALLK) - MS Wkly - November 6th, 2019
- Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) - Riverton Roll - September 25th, 2019
- Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) - TechNewsObserver - September 25th, 2019
- Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) - Mayfield Recorder - September 25th, 2019
- Artificially Engineering Intestine - Mirage News - September 25th, 2019
- Prothena Corporation plc (PRTA)'s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) - The EN Herald - September 25th, 2019
- cord_blood - Maryland - September 14th, 2019
- Stem Cells and Type 1 Diabetes: What the Future Has in ... - April 24th, 2019
- Stem Cell Therapy in Maryland | Stem Cell Professionals - April 5th, 2019
- Meristem - Wikipedia - January 17th, 2019
- Stem Cell Therapy in Annapolis Maryland | Stem Cell ... - October 25th, 2018
- Stem Cell Centers - Towson > Stem Cell Centers - October 6th, 2018
- STEM CELL THERAPY - Orthopedic and Wellness Maryland - September 5th, 2018
- Patient Resources | University of Maryland School of Medicine - September 5th, 2018
- Stem Cell Clinical Trial | University of Maryland Children ... - August 17th, 2018
- Baltimore, Maryland Stem Cell Transplants, Montgomery ... - August 17th, 2018
- Nervous System Stem Cells Can Replace Themselves, Give ... - July 3rd, 2018
- Excellence in Stem Cell Research | University of Maryland ... - June 24th, 2018
- Maryland Stem Cell Research Fund: 2014 Awardees - June 24th, 2018
- Catholic response to stem cells - Featured Today ... - October 14th, 2017
- Free stem cell Essays and Papers - 123HelpMe - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and Regenerate Your Body - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and ... - Mercola.com - September 4th, 2017
- Science and technology to get boost from CRS-12 mission - SpaceFlight Insider - August 12th, 2017
- Cannon Scholars visit National Institute of Standards and Technology - Dover Post - August 9th, 2017
- Lab-Grown, Virus-Free Stem Cells Repair Retinal Tissue in ... - August 9th, 2017
- Roanoke researchers pursue treatments for the type of deadly brain cancer affecting McCain - Roanoke Times - August 3rd, 2017
- The Maryland Stem Cell Research Fund (MSCRF) | Tedco - November 25th, 2016
- Center for Stem Cell Biology & Regenerative Medicine ... - November 14th, 2016
- Ginger | University of Maryland Medical Center - September 6th, 2016
- Johns Hopkins Team Creates Stem Cells From Schizophrenia ... - September 5th, 2016
- Human Induced Pluripotent Stem Cell Derived Neuronal Cells ... - August 18th, 2016
- Maryland Stem Cell Center Consortium and Core Facility ... - August 12th, 2016
- Human Stem Cells Institute - Wikipedia, the free encyclopedia - October 19th, 2015
- Patients' Own Genetically Altered Immune Cells Show ... - October 19th, 2015
- Maryland Stem Cell Research Fund: Funding Opportunities - July 2nd, 2015
- MRI based on a sugar molecule can tell cancerous from noncancerous cells - March 27th, 2015
- MD Stem Cells Release Optic Nerve Vision Loss Reversed ... - March 22nd, 2015
- TiGenix: TiGenix reports its full year 2014 results - March 18th, 2015
- Gene regulatory path revealed as target for therapy of aggressive pediatric brain cancer - March 10th, 2015
- American Spine offers experimental fix for pain -- Gazette.Net - January 28th, 2015
- American Spine offers experimental fix for pain - January 28th, 2015
- Toughest Breast Cancer May Have Met Its Match - December 9th, 2014
- Bid on Stem Cells and Alcohol-induced Tissue Injuries (R21 ... - November 12th, 2014
- Head, National Institutes of Health Stem Cell Technology ... - November 11th, 2014